US Capitol Capsule: Fixing REMS requires input, cooperation, FDA says
This article was originally published in Scrip
Executive Summary
US regulators acknowledged last week the FDA has run into challenges over the past five years in implementing risk evaluation and mitigation strategies (REMS) – enforceable, structured plans intended to manage specific risks associated with prescription medicines.